Krill Oil for Heart Health Support

Krill oil raises the omega-3 index efficiently per gram and modestly lowers triglycerides, but typical capsules contain only 100-200 mg of EPA and DHA, and no trial has shown it improves cardiovascular outcomes more than cheaper fish oil.

Phospholipid-bound EPA and DHA are incorporated directly into membrane phospholipid pools, altering the substrate available to phospholipase A2 and shifting eicosanoid production toward less inflammatory series and toward pro-resolving mediators such as resolvins. Higher membrane omega-3 content also reduces hepatic VLDL triglyceride secretion and stabilises cardiac myocyte membranes.

Head-to-head absorption studies consistently show krill oil raising the omega-3 index more per gram of EPA and DHA delivered than triglyceride or ethyl-ester fish oil, attributed to phospholipid emulsification that bypasses the need for bile-mediated lipase digestion. On lipids, randomised trials of krill oil at 1-4 g/day report triglyceride reductions in the range of 10-20% in people with elevated baseline values, with little effect in those already normal, plus small and inconsistent changes in HDL and LDL. The critical gap is outcomes: no cardiovascular event trial has been run on krill oil. What we have for fish oil at high dose — the REDUCE-IT and STRENGTH results, which themselves conflict — cannot simply be transferred to krill, and the doses used in those trials, 3-4 g/day of EPA and DHA, would require an impractical and expensive number of krill capsules. On current evidence krill is a good omega-3 delivery vehicle with a small absorption advantage and no demonstrated clinical superiority.

People with severe hypertriglyceridaemia needing 3-4 g/day of EPA and DHA, for whom capsule count and cost make krill impractical, and anyone whose lipid problem is driven by alcohol or uncontrolled diabetes.